2018 IDWeek, the Co-morbidities and Adverse Drug Reactions Workshop, and Glasgow*

IDWeek 2018; October 3-7, 2018; San Francisco, California
20th International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; October 13-14, 2018; New York, New York
HIV Drug Therapy Glasgow 2018; October 28-31, 2018; Glasgow, United Kingdom
Review the latest clinical findings from 3 important HIV meetings.
Daniel R. Kuritzkes, MD
Babafemi Taiwo, MBBS
David A. Wohl, MD

ClinicalThought

Preclinical and early-phase clinical data are promising for the novel HIV capsid inhibitor GS-6207 and the NRTTI MK-8591. What roles could these long-acting injectables potentially serve in our treatment armamentarium?

Babafemi Taiwo, MBBS Released: November 27, 2018

Concerning data from an ongoing study evaluating ART exposure during pregnancy underscore the need for more research on drug safety in early pregnancy. How do the results of other ART pregnancy safety analyses reported this fall contribute to the existing body of knowledge?

Daniel R. Kuritzkes, MD Released: December 13, 2018

What switch options can we offer to our patients with stable virologic suppression on older, more cumbersome ART regimens? Data from IAS, IDWeek, and Glasgow 2018 support novel booster-free options, including 2- and 3-drug combinations based on recently approved agents.

David A. Wohl, MD Released: January 23, 2019
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Educational grants provided by
Gilead Sciences
Janssen Therapeutics
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue